Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
4 hedge funds and large institutions have $2.11M invested in Lexaria Bioscience Warrant in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$794K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$638K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$173K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$98.7K |
Top Sellers
LEXXW Hedge Fund Activity: Q1 2021 in Review
4 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q1 2021, worth a combined $2.11M.
Buyers outnumbered sellers: 4 funds opened new LEXXW positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $794K.
- 4 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $2.11M of Lexaria Bioscience Warrant stock for Q1 2021.
- 4 funds opened new Lexaria Bioscience Warrant positions in Q1 2021 and 0 closed out, a net change of +4 holders.
- The largest Lexaria Bioscience Warrant buyer in Q1 2021 was Armistice Capital, an estimated $794K added.
Based on aggregated 13F filings for Q1 2021.